A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection

Launched by ZHEJIANG UNIVERSITY · Feb 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at patients with severe hepatitis, also known as liver failure, especially those who are dealing with infections at the same time. The main goal is to better understand the types of germs (like bacteria and viruses) that can complicate liver failure and how these infections affect recovery. By doing this study, researchers hope to create models that can help predict how patients might respond to treatment and tailor their care accordingly.

To be eligible for this study, participants should be between 18 and 70 years old, have been diagnosed with certain types of hepatitis (like hepatitis B or E), and show signs of worsening liver function, such as increased jaundice (yellowing of the skin and eyes) or significant bleeding risks. The study is currently not recruiting participants, but once it starts, those who join will help researchers gather important information that could improve treatment for future patients with liver failure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients agreed to participate in the study and signed an informed consent form;
• • 2. Sex is not limited and age is 18-70 years old;
• • 3. HBsAg positive for more than 6 months, or hepatitis E IgM positive, or hepatitis E RNA positive;
• • 4. Progressive deepening of jaundice in a short period of time (serum total bilirubin greater than 10 times the upper limit of normal or rising ≥17.1 umol/L per day);
• • 5. Sgnificant bleeding tendency with PTA ≤ 40% and exclusion of other non-hepatic factors.
• Exclusion Criteria:
• • 1. Patients with severe hepatitis caused by other non-hepatophilic viral infections;
• • 2. Patients who were considered by the investigator to be unsuitable for participation in the study.